Amir Zamani

Amir Zamani serves as a Principal at Bain Capital Life Sciences, a leading investment firm dedicated to partnering with and building innovative companies that are transforming healthcare. In his pivotal role, Mr. Zamani is instrumental in identifying, evaluating, and executing investment opportunities across the dynamic life sciences sector. He works closely with portfolio companies, providing strategic guidance and operational support to help them achieve their scientific and commercial milestones. His contributions are vital to Bain Capital Life Sciences' mission of backing groundbreaking advancements in medicine and technology that address significant unmet medical needs.

Mr. Zamani's investment focus at Bain Capital Life Sciences spans a broad spectrum of the life sciences industry. He is particularly interested in companies developing novel therapeutics, including those in biotechnology and pharmaceuticals, that target a wide range of diseases. His expertise also extends to medical devices, diagnostics, and life science tools, where he seeks out disruptive technologies and innovative platforms poised to redefine patient care and research capabilities. He is committed to supporting ventures that demonstrate strong scientific rigor, compelling clinical potential, and robust commercial viability.

Before joining Bain Capital Life Sciences, Amir Zamani honed his expertise at Flagship Pioneering, where he served as a Principal. Flagship Pioneering is renowned for its unique approach to company creation, originating and developing breakthrough biotech ventures from scientific discovery. This experience provided Mr. Zamani with invaluable insights into the foundational stages of life science innovation and company building. Prior to his tenure at Flagship, he was a management consultant at McKinsey & Company, focusing specifically on the healthcare sector. At McKinsey, he advised pharmaceutical, biotech, and medical device companies on strategic challenges, market entry, and operational improvements, further solidifying his understanding of the healthcare ecosystem.

Amir Zamani's robust academic background underpins his analytical prowess and deep scientific understanding. He earned his Ph.D. in Chemical Engineering from the Massachusetts Institute of Technology (MIT), a testament to his rigorous scientific training and research capabilities. He also holds a Bachelor of Science degree in Chemical Engineering from the University of California, Los Angeles (UCLA). This combination of advanced scientific education and extensive industry experience positions Mr. Zamani as a highly knowledgeable and strategic investor in the complex and rapidly evolving life sciences landscape. While specific individual investments are often part of a broader firm strategy, Mr. Zamani plays a key role in the firm's overall portfolio, contributing to investments in companies that are developing next-generation therapies for oncology, rare diseases, neurological disorders, and other critical health areas, as well as advanced medical technologies designed to improve patient outcomes globally.